Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan
Lake Street Capital Markets LLC engaged to act as an advisor to the Company Board…
Lake Street Capital Markets LLC engaged to act as an advisor to the Company Board…
LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with…
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company…
Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the…
VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Jan. 10, 2023 (GLOBE NEWSWIRE) — Atlas…
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10,…
Live video webcast on Wednesday, January 18th at 3:00 PM ET EDMONTON, Alberta, Jan. 10,…
Proprietary AMPS platform enables the systematic and rapid interrogation of protein-metabolite interactions to reveal new,…
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late-…
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to…
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO),…
REDWOOD CITY, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”…
Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected…
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023 Progress preclinical research…
IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”),…
— Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow…
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop…
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024…
Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a…